乌鸦传媒

Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab

One of 40 patients changed treatment but all remained on brentuximab regardless of scan results

Molecular or cytogenetic response at 3 months correlated with better survival

Newer therapies and strategies might show more promise for boosting survival

Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival

Risk of relapse was also lower in the group who received the cell therapy

Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs

Belamaf plus lenalidomide-dexamethasone achieved encouraging responses

Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit

About a third of patients, including those with TP53 mutations, achieved complete remission

Emphasis on novel biological approaches in treating patients with hematologic malignancies

Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint

Also at SOHO: Ponatinib proves mettle in pretreated CML

Objective responses in a majority of patients